Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 2 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 2 mg ropinirola (u obliku ropinirolklorida)

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 4 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 4 mg ropinirola (u obliku ropinirolklorida)

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 8 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 8 mg ropinirola (u obliku ropinirolklorida)

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 2 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 2 mg ropinirola u obliku ropinirolklorida

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 4 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 4 mg ropinirola u obliku ropinirolklorida

Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - ropinirolklorid - tableta s produljenim oslobađanjem - 8 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 8 mg ropinirola u obliku ropinirolklorida

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

d&a pharma - natrij oksibat - substance withdrawal syndrome; alcohol abstinence - ostali lijekovi protiv živčanog sustava - substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - vrsta ii za skladištenje glikogena - ostali prehrambeni proizvodi i proizvodi metabolizma - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 i 5.

Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.